Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris

被引:146
|
作者
Chams-Davatchi, Cheyda
Esmaili, Nafiseh
Daneshpazhooh, Maryam
Valikhani, Mahin
Balighi, Kamran
Hallaji, Zahra
Barzegari, Masoumeh
Akhyani, Maryam
Ghodsi, S. Zahra
Seirafi, Hassan
Tabrizi, Mohammad-Javad Nazemi
Mortazavi, Hossein
Mirshams-Shahshahani, Mostafa
机构
[1] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran 11996, Iran
[2] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Pemphigus Res Unit, Tehran, Iran
关键词
D O I
10.1016/j.jaad.2007.05.024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts. Objective: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy. Methods: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for I year at the Pemphigus Research Unit. Results: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P =.047). in the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P =.007), but not between P/A and P/PC (P =.971), and P/MM and P/PC (P =.670). Side effects were not significantly different among the 4 groups. Limitations: Larger sample sizes and blind design are suggested for future studies. Conclusion. The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycoplienolate mofetil.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 50 条
  • [11] Phenobarbitone versus Phenytoin for Treatment of Neonatal Seizures: An Open-label Randomized Controlled Trial
    Pathak, Garima
    Upadhyay, Amit
    Pathak, Umesh
    Chawla, Deepak
    Goel, Sneh P.
    INDIAN PEDIATRICS, 2013, 50 (08) : 753 - 757
  • [12] Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients
    Goh, M. S. Y.
    McCormack, C.
    Dinh, H. V.
    Welsh, B.
    Foley, P.
    Prince, H. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (05) : 990 - 996
  • [13] Open-label placebos for menopausal hot flushes: a randomized controlled trial
    Yiqi Pan
    Ramona Meister
    Bernd Löwe
    Ted J. Kaptchuk
    Kai J. Buhling
    Yvonne Nestoriuc
    Scientific Reports, 10
  • [14] Open-label placebos for menopausal hot flushes: a randomized controlled trial
    Pan, Yiqi
    Meister, Ramona
    Loewe, Bernd
    Kaptchuk, Ted J.
    Buhling, Kai J.
    Nestoriuc, Yvonne
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [15] Open-label placebos reduce weight in obesity: a randomized controlled trial
    Schaefer, Michael
    Kuehnel, Anja
    Enge, Soren
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [16] An Open-Label Controlled Trial of Theophylline for Treatment of Patients With Hyposmia
    Henkin, Robert I.
    Velicu, Irina
    Schmidt, Loren
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 337 (06): : 396 - 406
  • [17] Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial
    Seidman, Larry
    Kroll, Robin
    Howard, Brandon
    Ricciotti, Nancy
    Hsieh, Jennifer
    Weiss, Herman
    CONTRACEPTION, 2015, 91 (06) : 495 - 502
  • [18] Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
    Koshak, Abdulrahman E.
    Koshak, Emad A.
    Mobeireek, Abdullah F.
    Badawi, Mazen A.
    Wali, Siraj O.
    Malibary, Husam M.
    Atwah, Ali F.
    Alhamdan, Meshari M.
    Almalki, Reem A.
    Madani, Tariq A.
    COMPLEMENTARY THERAPIES IN MEDICINE, 2021, 61
  • [19] Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Jae-Min
    Lee, Seung-Hyun
    Lee, Jeong-Hoon
    Yoon, Bo-Hyun
    Yang, Su-Jin
    Hwang, Michael Y.
    Yoon, Jin-Sang
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (07): : 1504 - 1509
  • [20] A Randomized, Controlled, Open-label Trial Evaluating the Efficacy and Safety of Chloroquine in the Treatment of Giardiasis in Children
    Canete, R.
    Rivas, D. E.
    Escobedo, A. A.
    Gonzalez, M. E.
    Almirall, P.
    Brito, K.
    WEST INDIAN MEDICAL JOURNAL, 2010, 59 (06): : 607 - 611